Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Authors:
Xiaoju Wang
Xiaoju Wang
University of Michigan Medical School
United States
Yuanyuan Qiao
Yuanyuan Qiao
University of Michigan Medical School
United States
Irfan A Asangani
Irfan A Asangani
University of Michigan Medical School
United States
Bushra Ateeq
Bushra Ateeq
University of Michigan Medical School
United States
Anton Poliakov
Anton Poliakov
University of Alabama at Birmingham
United States
Marcin Cieslik
Marcin Cieslik
University of Virginia
United States
Sethuramasundaram Pitchiaya
Sethuramasundaram Pitchiaya
University of Michigan
United States

Cancer Cell 2017 06;31(6):844-847

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.05.001DOI Listing
June 2017
8 Reads

Publication Analysis

Top Keywords

gene fusion
4
fusion product
4
product prostate
4
prostate cancer
4
inhibitors erg
4
erg gene
4
peptidomimetic inhibitors
4
development peptidomimetic
4
prostate
1
cancer
1
inhibitors
1
product
1
development
1
fusion
1
erg
1
gene
1

Similar Publications

Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Neoplasia 2008 Feb;10(2):177-88

Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Read More

View Article
February 2008

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.

Br J Cancer 2007 Dec 30;97(12):1690-5. Epub 2007 Oct 30.

Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.

The prostate-specific gene, TMPRSS2 is fused with the gene for the transcription factor ERG in a large proportion of human prostate cancers. The prognostic significance of the presence of the TMPRSS2:ERG gene fusion product remains controversial. We examined prostate cancer specimens from 165 patients who underwent surgery for clinically localised prostate cancer between 1998 and 2006. Read More

View Article
December 2007

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Clin Cancer Res 2009 Jul 7;15(14):4706-11. Epub 2009 Jul 7.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Purpose: Fusion of the TMPRSS2 prostate-specific gene with the ERG transcription factor is a putatively oncogenic gene rearrangement that is commonly found in prostate cancer tissue from men undergoing prostatectomy. However, the prevalence of the fusion was less common in samples of transurethral resection of the prostate from a Swedish cohort of patients with incidental prostate cancer followed by watchful waiting, raising the question as to whether the high prevalence in prostatectomy specimens reflects selection bias. We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States. Read More

View Article
July 2009

Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.

Prostate 2017 Oct 28;77(14):1438-1445. Epub 2017 Aug 28.

Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

Background: Prostate cancer is considered to be highly heterogeneous, with various morphologic features and biologic behaviors. The TMPRSS2-ERG gene fusion is the most frequently observed genetic aberration in prostate cancer. The aim of this study was to elucidate the intrafocal heterogeneity of ERG gene fusion status. Read More

View Article
October 2017